| Original language | English (US) |
|---|---|
| Pages (from-to) | 525-533 |
| Number of pages | 9 |
| Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Volume | 39 |
| Issue number | 5 |
| DOIs | |
| State | Published - Feb 10 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, No. 5, 10.02.2021, p. 525-533.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Checkpoint Blockade in Lymphoma
AU - Ansell, Stephen M.
N1 - Funding Information: tures and received research funding from some organizations as described below. There was no financial support for this study. Akinobu Nakamura has received research funding from Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co. Ltd.; Naoki Manda has received honoraria for lectures from Ono Pharmaceutical Co. Ltd.; Yoshio Kurihara has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca, Mit-subishi Tanabe Pharma Co. Ltd., MSD, Ono Pharmaceutical Co. Ltd., Sanofi, Shionogi & Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; Tatsuya Atsumi has received honoraria for lectures from Mitsubishi Tanabe Pharma Co. Chugai Pharmaceutical Co. Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Ab-bVie Inc., Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Bristol-My-ers Squibb Co., UCB Japan Co. Ltd., Eli Lilly Japan K.K., and has received research funding from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., and Alexion Inc. Hideaki Miyoshi has received honoraria for lectures from As-tellas Pharma Inc., Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., MSD, Novartis Pharma, Novo Nordisk Pharma, Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Sanofi, and has received research funding from Astellas Pharma Inc., Dai-ichi Sankyo, Dainippon Pharma Co., Eli Lilly, Mitsubishi Ta-nabe Pharma Co., Novo Nordisk Pharma, Kowa Pharmaceutical Co., Abbott Japan Co., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Taisho Toyama Pharmaceutical Co., Ltd. The other authors declare no conflict of interest.
PY - 2021/2/10
Y1 - 2021/2/10
UR - http://www.scopus.com/inward/record.url?scp=85102083922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102083922&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.01522
DO - 10.1200/JCO.20.01522
M3 - Review article
C2 - 33434074
AN - SCOPUS:85102083922
SN - 0732-183X
VL - 39
SP - 525
EP - 533
JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
IS - 5
ER -